Loading stock data…
AC Immune SA (ACIU)
$2.58+0.03 (+0.98%)
Market OpenUpdated 2:07 PM EDT
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AC Immune SA in the Healthcare sector is trading at $2.58 with a market capitalization of $238M. Wall Street consensus targets $8.68 (4 analysts), implying a +235.7% move over the next 12 months. The stock is currently 35% below its 52-week high of $4.00, remaining 13.3% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +235.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.12M↑ | $338,000↓ | $939,000↓ | $1.31M↑ | $990,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$14.79M↓ | -$14.41M↑ | -$15.70M↑ | -$19.39M | -$19.37M |
| Net Income | -$14.80M↓ | -$14.37M↑ | -$15.86M↑ | -$21.19M↓ | -$19.03M |
Peer Comparison
JNJUNHPFE
Fundamentals
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The compa...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$238.15M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-210.00%
Volume
Today's trading volume
83,334
Recent News
June 2026 Penny Stocks To Watch For Potential Growth
Over the last 7 days, the market has remained flat, but it is up 24% over the past year, with earnings expected to grow by 19% per annum over the next few years. For investors willing to explore beyond well-known stocks, penny stocks — often representing smaller or newer companies — can present intriguing opportunities. Despite being a somewhat outdated term, penny stocks remain a relevant investment area for those seeking potential growth and financial resilience in lesser-known companies.
INDV and the Shift to Long-Acting Opioid Use Disorder Care in 2026
Long-acting injectable adoption remains low, but Indivior's market position, payer access and consumer campaign could help drive growth into 2026.
Is Indivior Stock a Buy After Higher 2026 Guidance?
Indivior raised 2026 guidance after strong Q1 results, but investors are watching whether Sublocade growth and margin gains can sustain momentum.
INDV Stock: What Sublocade Growth Signals for 2026
Sublocade is powering Indivior's growth with record patient starts, rising volumes and a stable market share, setting up key demand tests for 2026.
AC Immune (ACIU) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
AC Immune (ACIU) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.